BLR Bio says YAP-targeting peptide may help fight cancer drug resistance

BLR Bio says new research shows its peptide therapeutic can reduce YAP nuclear translocation, a pathway tied to treatment resistance in cancer. The company says the approach could support combination use with immunotherapies, KRAS inhibitors, ADCs and chemotherapy.

Why it matters: - Drug resistance is one of oncology’s biggest problems, and more than 90% of cancer-related deaths are attributed to treatment resistance. - BLR Bio’s approach is aimed at a resistance pathway that can weaken the effect of immunotherapies, KRAS inhibitors, antibody-drug conjugates and chemotherapy. - The company’s pitch is that the peptide may reduce YAP activity without fully shutting the pathway down, which could lower the risk of prolonged pathway suppression in healthy and cancer cells.

What happened: - BLR Bio announced new findings on Sept. 1, 2026, from research on its first-in-class Yes-Associated Protein translocation-modulating peptide therapeutic. - The company says the therapeutic reduced YAP nuclear translocation, a process linked to cancer resistance. - CEO Bruce Riser said stimulated YAP nuclear translocation in human cells was disrupted for less than six hours before returning to baseline. - The announcement says the work points to potential use in cancer and other serious diseases.

The details: - The research was published in Cells. - BLR Bio said earlier research showed the peptide enhanced gemcitabine efficacy in preclinical pancreatic cancer models. - The company said that result supports possible synergy with other therapies affected by YAP-mediated resistance. - The YAP-modulating effect was validated in cultured primary human fibroblasts. - BLR Bio described primary human fibroblasts as a relevant model for studying YAP biology in fibrosis. - The company said the new work provides the first indication of a potential cancer application from this biology. - The discovery came from collaborative work with scientists at the University of Saskatchewan and the University of Michigan. - BLR Bio said its primary laboratories are based in Rosalind Franklin University’s Helix 51 incubator. - BLR Bio said it continues to focus on developing therapies for fibrosis and cancer. - More information is available here.

Between the lines: - The data suggest BLR Bio is positioning YAP modulation as a way to tackle bypass resistance rather than a stand-alone cancer kill mechanism. - That matters because combination strategies often determine whether promising preclinical cancer programs can translate into broader clinical utility. - The company is also trying to distinguish its approach from other YAP-blocking therapies by emphasizing shorter pathway disruption.

What's next: - BLR Bio is likely to keep building preclinical evidence for cancer combinations, especially alongside immunotherapy, KRAS-targeted drugs, ADCs and chemotherapy. - Further validation will be needed to show whether the YAP-modulating effect translates into safer and more effective cancer treatment in humans. - The company’s broader development work remains centered on fibrosis and cancer.